We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights Archer-Daniels-Midland, Freeport-McMoRan, UnitedHealth, Casey's General Stores and Crane
Read MoreHide Full Article
For Immediate Release
Chicago, IL – November 6, 2026 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Archer-Daniels-Midland Co. (ADM - Free Report) , Freeport-McMoRan Inc. (FCX - Free Report) , UnitedHealth Group Inc. (UNH - Free Report) , Casey's General Stores Inc. (CASY - Free Report) and Crane Co. (CR - Free Report) .
Here are highlights from Thursday’s Analyst Blog:
Democratic Sweep May Turn the Tide in Favor of Cyclical Stocks: 5 Picks
Democrats have taken control of the U.S. Congress in the midterm poll sweeping both the Senate and House of Representatives. Following the resounding victory, U.S. stock markets skyrocketed.
Wall Street has been witnessing an astonishing bull run in the past four years predominantly supported by the enormous adoption of artificial intelligence (AI) technology. Massive growth of AI data centers and extraordinary spending of nearly a trillion dollars by major U.S. AI hyperscalers lifted prices of several AI-led stocks by more than 1000% in this period.
In the past two years, the Republican government led by President Donald Trump provided full support to massive AI data center build-out. However, a Democrat-led Congress may implement strict rules and regulations, revoke tax incentives and other governmental support for AI hyperscalers.
As a result, market participants may shift their preference toward cyclical sectors like industrials, financials, materials, retail and consumer-centric stocks from the current hot-cakes AI-driven technology and related stocks.
Here, we recommend five such stocks with a favorable Zacks Rank. These are: Archer-Daniels-Midland Co., Freeport-McMoRan Inc., UnitedHealth Group Inc.,Casey's General Stores Inc. and Crane Co..
Archer-Daniels-Midland has been benefiting from improving execution and strategic initiatives. ADM continues to advance its Optimize, Drive and Grow pillars, focusing on reliability, cost savings, throughput and organic growth.
The Nutrition segment is benefiting from Flavors growth, progress at Decatur East, Animal Nutrition improvements and demand for natural ingredients. ADM is also expanding opportunities through biosolutions, precision fermentation and decarbonization while improving asset utilization through debottlenecking.
Archer-Daniels-Midland has an expected revenue and earnings growth rate of 6.6% and 62.1%, respectively, for the current year. The Zacks Consensus Estimate for the current year's earnings has improved 1.8% over the last 30 days.
The short-term average price target of brokerage firms represents an increase of 18.6% from the last closing price of $70.84. The brokerage target price is currently in the range of $75-$95. This indicates a maximum upside of 34.1% and no downside.
Freeport-McMoRan Inc.
Freeport-McMoRan continues to leverage its portfolio of high-quality copper assets, emphasizing disciplined execution and organic growth initiatives to strengthen its production profile. FCX is conducting exploration activities near existing mines to expand reserves.
FCX is expected to gain from progress in its expansion projects that will boost production capacity. Freeport is executing several smelter projects in Indonesia. FCX is also well-positioned to benefit from automotive electrification, which is positive for copper, as electric vehicles are copper-intensive.
Freeport-McMoRan has an expected revenue and earnings growth rate of 15.6% and 71.8%, respectively, for the current year. The Zacks Consensus Estimate for the current year's earnings has improved 6.3% over the last 30 days.
The short-term average price target of brokerage firms represents an increase of 25.8% from the last closing price of $62.60. The brokerage target price is currently in the range of $48-$90. This indicates a maximum upside of 43.8% and a downside of 23.3%.
UnitedHealth Group Inc.
UnitedHealth Group's diversified operations and disciplined pricing support its growth prospects. Optum remains a key earnings driver, aided by integrated care, AI-enabled solutions and pharmacy services. Commercial fee-based membership gains and a healthy sales pipeline provide further opportunities.
Higher Medicare Advantage payment rates and improved medical cost management support UNH's earnings outlook. Cash generation also allows continued investment and shareholder returns. Healthcare demand also supports UNH's core business.
UnitedHealth Group has an expected revenue and earnings growth rate of 0.4% and 26.1%, respectively, for the current year. The Zacks Consensus Estimate for the current year's earnings has improved 4% over the last 30 days.
The short-term average price target of brokerage firms represents an increase of 16.2% from the last closing price of $409.38. The brokerage target price is currently in the range of $380-$531. This indicates a maximum upside of 29.7% and a downside of 7.2%.
Casey's General Stores Inc.
Casey's General Stores continues to benefit from solid inside sales momentum, supported by prepared foods, beverages and grocery categories. We expect CASY's inside same-store sales to increase 3.3% in fiscal 2027, while favorable sales mix and cost management support margin expansion.
Fuel remains a key earnings driver, benefiting from CASY's strong margins and an expanded store network. CEFCO conversions are increasing prepared-food sales and creating further growth opportunities as CASY expands its store base. Cash generation supports investment and shareholder returns.
Casey's General Stores has an expected revenue and earnings growth rate of 22% and 12.8%, respectively, for the current year (ending April 2027). The Zacks Consensus Estimate for the current year's earnings has improved 16.9% over the last 60 days.
The short-term average price target of brokerage firms represents an increase of 17.8% from the last closing price of $674.84. The brokerage target price is currently in the range of $687-$995. This indicates a maximum upside of 47.7% and no downside.
Crane Co.
Crane is engaged in the manufacture and sale of engineered industrial products in the United States, Canada, the United Kingdom, Continental Europe, and internationally. CR operates in two segments, Aerospace & Advanced Technologies and Process Flow Technologies. CR is a leading manufacturer of highly engineered components for challenging, mission-critical applications focused on the aerospace, defense, space and process industry end markets.
Crane has an expected revenue and earnings growth rate of 26.1% and 19.8%, respectively, for the current year. The Zacks Consensus Estimate for the current year's earnings has improved 3.6% over the last seven days.
The short-term average price target of brokerage firms represents an increase of 19% from the last closing price of $206.38. The brokerage target price is currently in the range of $234-$260. This indicates a maximum upside of 26% and no downside.
Research Chief Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
View the Zacks #1 Rank List
Image: Bigstock
The Zacks Analyst Blog Highlights Archer-Daniels-Midland, Freeport-McMoRan, UnitedHealth, Casey's General Stores and Crane
For Immediate Release
Chicago, IL – November 6, 2026 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Archer-Daniels-Midland Co. (ADM - Free Report) , Freeport-McMoRan Inc. (FCX - Free Report) , UnitedHealth Group Inc. (UNH - Free Report) , Casey's General Stores Inc. (CASY - Free Report) and Crane Co. (CR - Free Report) .
Here are highlights from Thursday’s Analyst Blog:
Democratic Sweep May Turn the Tide in Favor of Cyclical Stocks: 5 Picks
Democrats have taken control of the U.S. Congress in the midterm poll sweeping both the Senate and House of Representatives. Following the resounding victory, U.S. stock markets skyrocketed.
Wall Street has been witnessing an astonishing bull run in the past four years predominantly supported by the enormous adoption of artificial intelligence (AI) technology. Massive growth of AI data centers and extraordinary spending of nearly a trillion dollars by major U.S. AI hyperscalers lifted prices of several AI-led stocks by more than 1000% in this period.
In the past two years, the Republican government led by President Donald Trump provided full support to massive AI data center build-out. However, a Democrat-led Congress may implement strict rules and regulations, revoke tax incentives and other governmental support for AI hyperscalers.
As a result, market participants may shift their preference toward cyclical sectors like industrials, financials, materials, retail and consumer-centric stocks from the current hot-cakes AI-driven technology and related stocks.
Here, we recommend five such stocks with a favorable Zacks Rank. These are: Archer-Daniels-Midland Co., Freeport-McMoRan Inc., UnitedHealth Group Inc.,Casey's General Stores Inc. and Crane Co..
These stocks have provided double-digit returns year to date and have double-digit upside potential in the short term. Each of our picks currently carries a Zacks Rank # 2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
Archer-Daniels-Midland Co.
Archer-Daniels-Midland has been benefiting from improving execution and strategic initiatives. ADM continues to advance its Optimize, Drive and Grow pillars, focusing on reliability, cost savings, throughput and organic growth.
The Nutrition segment is benefiting from Flavors growth, progress at Decatur East, Animal Nutrition improvements and demand for natural ingredients. ADM is also expanding opportunities through biosolutions, precision fermentation and decarbonization while improving asset utilization through debottlenecking.
Archer-Daniels-Midland has an expected revenue and earnings growth rate of 6.6% and 62.1%, respectively, for the current year. The Zacks Consensus Estimate for the current year's earnings has improved 1.8% over the last 30 days.
The short-term average price target of brokerage firms represents an increase of 18.6% from the last closing price of $70.84. The brokerage target price is currently in the range of $75-$95. This indicates a maximum upside of 34.1% and no downside.
Freeport-McMoRan Inc.
Freeport-McMoRan continues to leverage its portfolio of high-quality copper assets, emphasizing disciplined execution and organic growth initiatives to strengthen its production profile. FCX is conducting exploration activities near existing mines to expand reserves.
FCX is expected to gain from progress in its expansion projects that will boost production capacity. Freeport is executing several smelter projects in Indonesia. FCX is also well-positioned to benefit from automotive electrification, which is positive for copper, as electric vehicles are copper-intensive.
Freeport-McMoRan has an expected revenue and earnings growth rate of 15.6% and 71.8%, respectively, for the current year. The Zacks Consensus Estimate for the current year's earnings has improved 6.3% over the last 30 days.
The short-term average price target of brokerage firms represents an increase of 25.8% from the last closing price of $62.60. The brokerage target price is currently in the range of $48-$90. This indicates a maximum upside of 43.8% and a downside of 23.3%.
UnitedHealth Group Inc.
UnitedHealth Group's diversified operations and disciplined pricing support its growth prospects. Optum remains a key earnings driver, aided by integrated care, AI-enabled solutions and pharmacy services. Commercial fee-based membership gains and a healthy sales pipeline provide further opportunities.
Higher Medicare Advantage payment rates and improved medical cost management support UNH's earnings outlook. Cash generation also allows continued investment and shareholder returns. Healthcare demand also supports UNH's core business.
UnitedHealth Group has an expected revenue and earnings growth rate of 0.4% and 26.1%, respectively, for the current year. The Zacks Consensus Estimate for the current year's earnings has improved 4% over the last 30 days.
The short-term average price target of brokerage firms represents an increase of 16.2% from the last closing price of $409.38. The brokerage target price is currently in the range of $380-$531. This indicates a maximum upside of 29.7% and a downside of 7.2%.
Casey's General Stores Inc.
Casey's General Stores continues to benefit from solid inside sales momentum, supported by prepared foods, beverages and grocery categories. We expect CASY's inside same-store sales to increase 3.3% in fiscal 2027, while favorable sales mix and cost management support margin expansion.
Fuel remains a key earnings driver, benefiting from CASY's strong margins and an expanded store network. CEFCO conversions are increasing prepared-food sales and creating further growth opportunities as CASY expands its store base. Cash generation supports investment and shareholder returns.
Casey's General Stores has an expected revenue and earnings growth rate of 22% and 12.8%, respectively, for the current year (ending April 2027). The Zacks Consensus Estimate for the current year's earnings has improved 16.9% over the last 60 days.
The short-term average price target of brokerage firms represents an increase of 17.8% from the last closing price of $674.84. The brokerage target price is currently in the range of $687-$995. This indicates a maximum upside of 47.7% and no downside.
Crane Co.
Crane is engaged in the manufacture and sale of engineered industrial products in the United States, Canada, the United Kingdom, Continental Europe, and internationally. CR operates in two segments, Aerospace & Advanced Technologies and Process Flow Technologies. CR is a leading manufacturer of highly engineered components for challenging, mission-critical applications focused on the aerospace, defense, space and process industry end markets.
Crane has an expected revenue and earnings growth rate of 26.1% and 19.8%, respectively, for the current year. The Zacks Consensus Estimate for the current year's earnings has improved 3.6% over the last seven days.
The short-term average price target of brokerage firms represents an increase of 19% from the last closing price of $206.38. The brokerage target price is currently in the range of $234-$260. This indicates a maximum upside of 26% and no downside.
Research Chief Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.
Free: See Our Top Stock And 4 Runners Up
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.